Navigation Links
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Date:11/1/2007

Data Presented at the 2nd Annual International Workshop on Hepatitis C

Resistance & New Compounds

WATERTOWN, Mass., Nov. 1 /PRNewswire/ -- Researchers from Enanta Pharmaceuticals today presented data on novel Hepatitis C protease inhibitors with potent antiviral activity in the cell-based replicon assay and favorable pre-clinical pharmacokinetic properties with the potential for once-daily dosing in humans.

The hepatitis C virus (HCV) increases a person's chances of developing chronic liver disease, and affects more than 170 million people worldwide. Current treatment options are not sufficient. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.

The abstract, "Potent HCV protease inhibitors with the potential for once-daily dosing," was presented today in a session focused on protease inhibitors at 8:30 a.m. during the 2nd Annual International Workshop on Hepatitis C Resistance & New Compounds in Boston.

"These compounds have demonstrated remarkable potency in the antiviral replicon assay and favorable pre-clinical pharmacokinetic properties supporting the potential for once-daily dosing in humans," said Yat Sun Or, Senior Vice President, Research and Development of Enanta Pharmaceuticals. "These data demonstrate our commitment to the discovery of next-generation protease inhibitors that will enhance the treatment options for patients who are infected with hepatitis C."

Abbott and Enanta Pharmaceuticals formed a collaboration in 2006 to develop and commercialize HCV protease inhibitors. The partnership leverages Abbott's innovative work in the protease inhibitor field against the Human Immunodeficiency Virus (HIV) and leadership in the area of antiviral therapies and Enanta's core expertise in chemistry and drug discovery. The HCV NS 3/4A serine protease is the focus of the collaboration.

About Hepatitis C Virus

Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and current therapies only provide sustained benefit in about half of patients with the genotype1 form of the virus.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. At the heart of Enanta is its commitment to innovative chemistry that surpasses traditional medicinal chemistry approaches. Enanta is developing novel protease and polymerase inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides that overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA. Enanta is a privately held company with offices in Watertown, MA. More information about the company can be found at http://www.enanta.com.

Enanta Contact

For Enanta Investor Relations, please contact:

Paul Mellett

617-607-0761

For Enanta Public Relations, please contact:

Jennifer Greenleaf

MacDougall Biomedical Communications

508-647-0209


'/>"/>
SOURCE Enanta Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. New Information on the Potential of Plasmin Shared at ISTH Congress
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
8. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
9. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):